[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzPE7GX1tVJt3XMEgd5crEiKPU9eIl58zxBqnAk7CMO8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Ostfold Hospital Trust",[4],50,false,12,5,42141,2,39,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Ankle Fractures",4,{"name":18,"count":19},"Pain, Postoperative",3,{"name":21,"count":11},"Postoperative Pain",{"name":23,"count":11},"Fecal Incontinence",{"name":25,"count":11},"Hallux Valgus",{"name":27,"count":11},"Deltoid Ligament; Sprain (Strain) (Ankle)",{"name":29,"count":11},"Attention Deficit Hyperactivity Disorder",{"name":31,"count":11},"Urinary Incontinence",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT07051915","The Holistic Study","2028-01-31","Avatrombopag",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,95,113,148,173,199,217,235,253,279,304,332,359,377],{"intervention":47,"totalTrials":19,"cells":48},"Rituximab",{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":91,"NA":93},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":90,"soonestReadout":36},[58,70,79],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":68},"NCT03010202","The PROLONG Trial - Rituximab Maintenance Therapy in ITP","UNKNOWN",[42],"2024-12","2016-12",136,[67],"Purpura, Thrombocytopenic, Idiopathic",[69,47],"Dexamethasone",{"nctId":34,"briefTitle":35,"status":71,"phases":72,"primaryCompletion":36,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":78},"NOT_YET_RECRUITING",[42],"2029-12-31","2025-09-15",220,[77],"Thrombocytopenia Purpura",[37,47],{"nctId":80,"briefTitle":81,"status":82,"phases":83,"primaryCompletion":84,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"NCT00344149","Rituximab as Second Line Treatment for ITP","COMPLETED",[42],"2014-03","2006-06",112,[88],"Immune Thrombocytopenia (ITP)",[47],1,{"trials":92,"activeCount":51},[],{"trials":94,"activeCount":51},[],{"intervention":37,"totalTrials":90,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":109,"NA":111},{"trials":98,"activeCount":51},[],{"trials":100,"activeCount":51},[],{"trials":102,"activeCount":51},[],{"trials":104,"activeCount":90,"soonestReadout":36},[105],{"nctId":34,"briefTitle":35,"status":71,"phases":106,"primaryCompletion":36,"completion":73,"start":74,"enrollment":75,"conditions":107,"interventions":108},[42],[77],[37,47],{"trials":110,"activeCount":51},[],{"trials":112,"activeCount":51},[],{"intervention":114,"totalTrials":11,"cells":115},"Methylphenidate",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":132,"PHASE4":134,"NA":146},{"trials":117,"activeCount":51},[],{"trials":119,"activeCount":51},[],{"trials":121,"activeCount":51},[122],{"nctId":123,"briefTitle":124,"status":82,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":131},"NCT02695355","ERP Based Single-dose Predictions of Stimulants",[41],"2013-01","2015-09","2006-10",87,[29],[114],{"trials":133,"activeCount":51},[],{"trials":135,"activeCount":51},[136],{"nctId":137,"briefTitle":138,"status":82,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":144},"NCT01220440","Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD",[43],"2008-12","2006-01",36,[29],[114,145],"Dextroamphetamine",{"trials":147,"activeCount":51},[],{"intervention":149,"totalTrials":90,"cells":150},"Naproxen 500 Mg",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":171},{"trials":152,"activeCount":51},[],{"trials":154,"activeCount":51},[],{"trials":156,"activeCount":51},[],{"trials":158,"activeCount":51},[],{"trials":160,"activeCount":51},[161],{"nctId":162,"briefTitle":163,"status":82,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT03347929","NSAIDs in Sciatica NSAIDS IN SCIATICA",[43],"2023-06-22","2017-11-30",123,[169],"Sciatica",[149],{"trials":172,"activeCount":51},[],{"intervention":174,"totalTrials":90,"cells":175},"Lidocaine spray",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":197},{"trials":177,"activeCount":51},[],{"trials":179,"activeCount":51},[],{"trials":181,"activeCount":51},[],{"trials":183,"activeCount":51},[],{"trials":185,"activeCount":51},[186],{"nctId":187,"briefTitle":188,"status":61,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT03031808","Comparison of Two Induction Regimens Using Topical Lidocaine or Muscle Relaxant on Sore Throat and Hemodynamics",[43],"2020-12-31","2017-10-31",100,[194],"Intubation Complication",[174,196],"Muscle Relaxant",{"trials":198,"activeCount":51},[],{"intervention":196,"totalTrials":90,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":51},[],{"trials":204,"activeCount":51},[],{"trials":206,"activeCount":51},[],{"trials":208,"activeCount":51},[],{"trials":210,"activeCount":51},[211],{"nctId":187,"briefTitle":188,"status":61,"phases":212,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":213,"interventions":214},[43],[194],[174,196],{"trials":216,"activeCount":51},[],{"intervention":145,"totalTrials":90,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":51},[],{"trials":222,"activeCount":51},[],{"trials":224,"activeCount":51},[],{"trials":226,"activeCount":51},[],{"trials":228,"activeCount":51},[229],{"nctId":137,"briefTitle":138,"status":82,"phases":230,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":231,"interventions":232},[43],[29],[114,145],{"trials":234,"activeCount":51},[],{"intervention":69,"totalTrials":90,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":249,"NA":251},{"trials":238,"activeCount":51},[],{"trials":240,"activeCount":51},[],{"trials":242,"activeCount":51},[],{"trials":244,"activeCount":51},[245],{"nctId":59,"briefTitle":60,"status":61,"phases":246,"primaryCompletion":63,"completion":63,"start":64,"enrollment":65,"conditions":247,"interventions":248},[42],[67],[69,47],{"trials":250,"activeCount":51},[],{"trials":252,"activeCount":51},[],{"intervention":254,"totalTrials":90,"cells":255},"Rivaroxaban",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":275,"NA":277},{"trials":257,"activeCount":51},[],{"trials":259,"activeCount":51},[],{"trials":261,"activeCount":51},[],{"trials":263,"activeCount":51},[264],{"nctId":265,"briefTitle":266,"status":82,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT02486445","Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study",[42],"2018-11-30","2018-12-30","2015-03",625,[273],"Deep Venous Thrombosis",[254],{"trials":276,"activeCount":51},[],{"trials":278,"activeCount":51},[],{"intervention":280,"totalTrials":90,"cells":281},"Daratumumab",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":283,"activeCount":51},[],{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[288],{"nctId":289,"briefTitle":290,"status":61,"phases":291,"primaryCompletion":292,"completion":63,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT04703621","The DART Study- Daratumumab Treatment in ITP",[41],"2024-04","2021-01-21",21,[296],"ITP",[280],{"trials":299,"activeCount":51},[],{"trials":301,"activeCount":51},[],{"trials":303,"activeCount":51},[],{"intervention":305,"totalTrials":90,"cells":306},"Desflurane",{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":326,"PHASE4":328,"NA":330},{"trials":308,"activeCount":51},[],{"trials":310,"activeCount":51},[],{"trials":312,"activeCount":51},[313],{"nctId":314,"briefTitle":315,"status":82,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":325},"NCT03727607","TIVA Versus Desfluran Anaesthesia in Patients Undergoing Bariatric Surgery",[41],"2017-12-11","2018-03-14","2016-01-30",160,[322,305,323,18,324],"Total Intravenous Anesthesia","Obesity","Nausea, Postoperative",[305],{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[],{"trials":331,"activeCount":51},[],{"intervention":333,"totalTrials":90,"cells":334},"Oksykodonhydroklorid",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":336,"activeCount":51},[],{"trials":338,"activeCount":51},[],{"trials":340,"activeCount":51},[],{"trials":342,"activeCount":51},[],{"trials":344,"activeCount":51},[],{"trials":346,"activeCount":51},[347],{"nctId":348,"briefTitle":349,"status":82,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT03023462","Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair",[44],"2020-06-30","2019-09-05",60,[355,18],"Inguinal Hernia",[333,357,358],"Ondansetron and Droperidol","Ropivacaine",{"intervention":357,"totalTrials":90,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":362,"activeCount":51},[],{"trials":364,"activeCount":51},[],{"trials":366,"activeCount":51},[],{"trials":368,"activeCount":51},[],{"trials":370,"activeCount":51},[],{"trials":372,"activeCount":51},[373],{"nctId":348,"briefTitle":349,"status":82,"phases":374,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":375,"interventions":376},[44],[355,18],[333,357,358],{"intervention":358,"totalTrials":90,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":380,"activeCount":51},[],{"trials":382,"activeCount":51},[],{"trials":384,"activeCount":51},[],{"trials":386,"activeCount":51},[],{"trials":388,"activeCount":51},[],{"trials":390,"activeCount":51},[391],{"nctId":348,"briefTitle":349,"status":82,"phases":392,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":393,"interventions":394},[44],[355,18],[333,357,358]]